How to Providing Personalized Cancer Vaccines and Cancer Vaccines

• 1. 个性化癌症疫苗的制备方法 [P] . 中国专利： CN109865133B . 2021.07.09
• 2. 个性化癌症疫苗表位选择 [P] . 中国专利： CN113365639A . 2021-09-07
• 3. INDIVIDUALIZED CANCER VACCINES AND METHODS FOR PROVIDING CANCER VACCINES [P] . 日本专利： JP2019038837A . 2019-03-14

  机译： 个体化的癌症疫苗和提供癌症疫苗的方法

• 4. Cancer mutation selection to create personalized cancer vaccines [P] . KR20210092723A . 2021-07-26

  机译： 癌症突变选择创造个性化癌症疫苗

• 5. SELECTION OF CANCER MUTATIONS FOR GENERATION OF A PERSONALIZED CANCER VACCINE [P] . EP3881324A1 . 2021-09-22

  机译： 用于生成个性化癌症疫苗的癌症突变的选择

• 1. Immunoengineering through cancer vaccines - A personalized and multi-step vaccine approach towards precise cancer immunity [J] . Lybaert Lien, Vermaelen Karim, De Geest Bruno G., Journal of Controlled Release: Official Journal of the Controlled Release Society . 2018,第期
• 2. Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine [J] . Mark O Hardin, Timothy J Vreeland, Guy T Clifton, Immunotherapy . 2018,第5期
• 3. The perfect personalized cancer therapy: cancer vaccines against neoantigens [J] . Luigi Aurisicchio, Matteo Pallocca, Gennaro Ciliberto, Journal of experimental & clinical cancer research : . 2018,第1期
• 4. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1
• 5. Personalized Cancer Vaccine Development for Brain and Colon Cancers Using Synthetic HDL Nanoparticles [D] . Scheetz, Lindsay. 2020
• 6. Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer [O] . Janos L. Tanyi, Cheryl L.-L. Chiang, Johanna Chiffelle, 2021
• 7. Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer [O] . Janos L. Tanyi, Cheryl L.-L. Chiang, Johanna Chiffelle, 2021

• 1. The Heat Shock Protein Story—From Taking mTORC1,2 and Heat Shock Protein Inhibitors as Therapeutic Measures for Treating Cancers to Development of Cancer Vaccines [J] . Peter Chin Wan Fung ,Regina Kit Chee Kong . 癌症治疗（英文） . 2017,第11期
• 2. Cyclooxygenase Inhibition in Cancer Immunotherapy: Combination of Indomethacin with Cancer Vaccines Is Not Always Beneficial [J] . Giselle Hevia ,Isabel Pablos ,Marilyn Clavell . 癌症治疗（英文） . 2017,第2期
• 3. Advances in inducing adaptive immunity using cell-based cancer vaccines: clinical applications in pancreatic cancer [J] . Mikio Kajihara ,Kazuki Takakura ,Tomoya Kanai . 世界胃肠病学杂志：英文版 . 2016,第18期
• 4. Therapeutic MUC1-Based Cancer Vaccine Expressed in Flagella-Efficacy in an Aggressive Model of Breast Cancer [J] . Nathalie Machluf ,Ruth Arnon . 疫苗（英文） . 2012,第3期
• 5. Cancer Immunothearapy More than Vaccines “Psychoneuro-Immunooncology: Cancer, the Host, and the Surgeon” [J] . Robert Lange Elliott . 癌症治疗（英文） . 2011,第3期
• 6. 癌症疫苗发展趋势分析 [C] . 汪楠 ,田玲 ,王敏 . 中国医学科学院/北京协和医学院医学信息研究所/图书馆2009年学术年会 . 2010
• 7. MUC1-survivin治疗性癌症疫苗的药代动力学与组织分布研究 [A] . 周仪 . 2020